Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
3 Dividend Aristocrats to Own For a Lifetime Of Passive Income
20.05.2026 17:45
Paychecks stop. Bonuses get cut. Layoff announcements arrive without warning. Dividend checks, by contrast, keep landing in brokerage accounts on a schedule set years in advance by boards that treat the payout like a contract with shareholders. For income investors, that predictability is the whole point. A portfolio of mature, cash-rich businesses that have raised ... 3 Dividend Aristocrats to Own For a Lifetime Of Passive Income
Can a New Arthritis Drug Make Immunovant the Next Biotech Star?
20.05.2026 17:20
Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
20.05.2026 15:38
Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
20.05.2026 14:43
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer
20.05.2026 12:54
Compare JNJ vs. PFE: Why Johnson & Johnsonâs stability, dividend growth, and buybacks may beat Pfizerâs low valuation and high yield. Read the full analysis here.
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
20.05.2026 12:30
LARGO, Fla., May 20, 2026--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors ("Board"), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of n
How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer
20.05.2026 12:00
Nanobiotix wants to fundamentally change a century-old mainstay in battling cancer. The top-notch biotech stock is flying.
Kenvue tracks packaging through recycling stream with Greyparrot’s AI
20.05.2026 10:50
The collaboration spotlights use cases for AI in packaging, such as pinpointing the optimal hue for shampoo bottles to ensure recyclability. Identifying design changes gains importance as the packaging regulation landscape widens.
NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty
20.05.2026 06:42
NRx Pharmaceuticals (NRXP) is downgraded from 'Buy' to 'Sell' following failures in ZYESAMI and NRX-101 clinical trials.
Meet the Dividend King With a Higher Credit Rating Than the U.S. Government
19.05.2026 11:50
It has plenty of other qualities investors should take note of.
Johnson And Johnson Catheter Launch Adds New Angle To JNJ Valuation
19.05.2026 09:11
Johnson & Johnson (NYSE:JNJ) has launched the next generation Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease. The device is designed to improve flexibility, lesion crossing, and repositioning in complex coronary cases. The launch is positioned as a global rollout, targeting physicians treating patients with hardened coronary lesions. For investors watching NYSE:JNJ, this product introduction sits alongside a share price of $228.92 and multi year returns of...
Update: Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case
19.05.2026 08:15
(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o
Is It Time To Reassess Johnson & Johnson (JNJ) After Its 54% One Year Rally?
18.05.2026 01:22
If you are wondering whether Johnson & Johnson at around US$226.71 is still a strong long term holding or starting to look stretched, the answer starts with understanding what you are really paying for today. The stock is up 2.4% over the past week, down 3.2% over the past month, and sits on a 9.3% year to date return, with a 54.0% one year return, 56.0% over three years, and 52.7% over five years. This gives you a wide range of recent price behaviour to put under the microscope. Recent...
Johnson & Johnson Lung Cancer Data Adds Dimension To Oncology Valuation Story
18.05.2026 00:50
Johnson & Johnson (NYSE:JNJ) presented early clinical data on JNJ-1900 (NBTXR3) for inoperable non-small cell lung cancer at the 2026 ESTRO Annual Meeting. The company shared positive Phase 2 feasibility and safety results for this nanoradioenhancer candidate in a high unmet medical need setting. The update highlights progress in Johnson & Johnson's late-stage oncology portfolio and adds a new element to its cancer care pipeline. Johnson & Johnson, known for its diversified healthcare...
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
17.05.2026 14:15
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual MeetingPARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson & Johnson-sp
How The Story For Johnson & Johnson (JNJ) Is Shifting With New Drugs And Legal Twists
15.05.2026 01:29
The intrinsic value estimate for Johnson & Johnson has shifted slightly, with the fair value moving from US$252.42 to US$252.96 per share, a change of about 0.2%. That subtle move lines up with recent analyst research that focuses on execution around drugs like Icotyde, Inlexzo, Tecvayli and Tremfya, as well as on how the pipeline and broader healthcare positioning are shaping sentiment. As you read on, you will see how these price target tweaks fit into the wider story and what to watch as...
Jim Cramer on CoreWeave: “A Stock That’s Not for the Squeamish”
14.05.2026 15:40
CoreWeave, Inc. (NASDAQ:CRWV) was among the stocks on Jim Cramer’s radar as he highlighted the importance of lower interest rates in sustaining the broader market rally. Answering a caller’s query about the stock during the episode, Cramer said: Okay, now, I gotta tell you… CoreWeave is what I call a stock that’s not for the […]
Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?
14.05.2026 15:30
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rubicon Point Partners Acquires Shockwave Medical Headquarters Campus in Santa Clara, California
14.05.2026 13:06
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Rubicon Point Partners (“RPP”) announces the acquisition of the Shockwave Medical headquarters, a 201,078-square-foot, four-building R&D campus in Santa Clara, California, on behalf of Rubicon Point Fund II. The property is 100% NNN leased to Shockwave Medical, Inc., a medical device company and wholly owned subsidiary of Johnson & Johnson (S&P: AAA). “This is the beginning of a billion dollar investment strategy that we plan to deploy over the com
CAPLYTA Data Highlights Johnson & Johnson Valuation And Mental Health Story
14.05.2026 12:14
Johnson & Johnson's CAPLYTA (lumateperone) showed superior efficacy and favorable safety in major depressive disorder in a new network meta-analysis. The study compared CAPLYTA to other FDA approved antipsychotics used as adjunctive treatment for major depressive disorder. Results were presented at a major neuroscience meeting, highlighting comparative effectiveness and tolerability versus competing therapies. For investors tracking NYSE:JNJ, this update on CAPLYTA arrives with the stock at...